Search

314 results for "lecanemab".

Research summaries 285

Showing the best 200 of 285, 131–140, page 14 of 20. Filter these by subject, year and score in the research library →

1. Advances in immunotherapy for Alzheimer's Disease 2020-2023 – a literature reviewResearch summary

   Research summaries · alzhub.org/study/advances-in-immunotherapy-for-alzheimer-s-disease-2020-2023-a-aa1cc3c7

   … aducanumab, donanemab and lecanemab are particularly noteworthy. Lecanemab and aducanumab are already registered in the US, among others. More studies should be expected to try to solve the problems of qualifying patients into …

2. Comparisons of efficacy and safety of immunotherapies for Alzheimer's disease treatment: A network meta-analysis of randomised controlled trialsResearch summary

   Research summaries · alzhub.org/study/comparisons-of-efficacy-and-safety-of-immunotherapies-for-alzheimer-s-40473116

   Fifty-nine RCTs were included. Donanemab and lecanemab ranked among the most effective treatments for improving cognitive function (Clinical Dementia Rating Scale - Sum of Boxes P-scores: 0.88 and 0.77) and daily activities …

3. Elevated soluble amyloid beta protofibrils in Down syndrome and Alzheimer's diseaseResearch summary

   Research summaries · alzhub.org/study/elevated-soluble-amyloid-beta-protofibrils-in-down-syndrome-and-34091073

   … the antibody BAN2401 (lecanemab) in DS and AD compared with NDC. These data and the promising data in a large phase 2 CE clinical trial with lecanemab suggest that lecanemab may have the potential to preserve cognitive capacity …

4. Evaluating the Cost-Effectiveness of Pharmacological Therapy in Alzheimer Disease in BrazilResearch summary

   Research summaries · alzhub.org/study/evaluating-the-cost-effectiveness-of-pharmacological-therapy-in-40435868

   … per QALY of $5211. For lecanemab versus SoC, the cost per QALY gained was $2 098 225, whereas donanemab versus lecanemab was $1 460 400. The SoC is a cost-effective pharmacological intervention for AD, offering the lowest cost …

5. Influence of patient characteristics on efficacy and safety of anti-amyloid monoclonal antibodies in Alzheimer's disease: A systematic review and meta-analysisResearch summary

   Research summaries · alzhub.org/study/influence-of-patient-characteristics-on-efficacy-and-safety-of-anti-41352683

   Background Lecanemab and donanemab are the first anti-amyloid monoclonal antibodies (mAbs) clinically available as disease-modifying therapies for Alzheimer's disease (AD). However, it remains unclear whether their treatment …

6. New and emerging drug therapies for Alzheimer diseaseResearch summary

   Research summaries · alzhub.org/study/new-and-emerging-drug-therapies-for-alzheimer-disease-38962384

   … protein (aducanumab and lecanemab) have been approved in the USA, and two agents (lecanemab and donanemab) are under evaluation by the Therapeutic Goods Administration in Australia. This review states that established drug …

7. Potential impact of unblinding on observed treatment effects in Alzheimer's disease trialsResearch summary

   Research summaries · alzhub.org/study/potential-impact-of-unblinding-on-observed-treatment-effects-in-38380503

   In trials of lecanemab, aducanumab, and donanemab, incidence of amyloid-related imaging abnormalities with active treatment ranged from 22% to 44%, the vast majority of which presumably led to unblinding. Effects of unblinding on …

8. Treating Alzheimer Disease With Antiamyloid Therapies—The Real-World Experience GrowsResearch summary

   Research summaries · alzhub.org/study/treating-alzheimer-disease-with-antiamyloid-therapiesthe-real-world-40844810

   … and effectiveness of lecanemab and donanemab in treating mild cognitive impairment and early Alzheimer disease outside clinical trials. This news article discusses the safety and effectiveness of lecanemab and donanemab for mild …

9. A systematic review of the efficacy and safety of anti-amyloid beta monoclonal antibodies in treatment of Alzheimer's diseaseResearch summary

   Research summaries · alzhub.org/study/a-systematic-review-of-the-efficacy-and-safety-of-anti-amyloid-beta-39432414

   According to CDR-SB measurements, lecanemab showed effectiveness in reducing brain amyloid and cognitive decline, with a change from baseline of 1.21. Aducanumab resulted in a decrease of -0.39 (-22%). Bapineuzumab showed no …

10. Alzheimer's Amyloid Hypothesis and Antibody Therapy: Melting Glaciers?Research summary

    Research summaries · alzhub.org/study/alzheimer-s-amyloid-hypothesis-and-antibody-therapy-melting-glaciers-38612701

    … antibodies, aducanumab and lecanemab, have been approved by the U.S. Food and Drug Administration, while a third, donanemab, is under review. The main argument for the FDA approvals is a presumed therapy-induced removal of …

How this search works

There is no outside search company involved. The site builds its own index by reading its own pages — the same words you would see on the page — and each result shows a literal snippet of that text with your words highlighted. Nothing is summarised or rewritten by a machine in between.

One addition, made by hand: a short list of everyday words that our pages cover under another name. Search "symptoms" and you are also shown The 10 warning signs; "medication" leads to Treatments & medicines; "hotline" to the helplines. A result reached that way shows the page's own description, and it only ever points to a page that already covers the subject.

28781 pages, questions, glossary terms and research summaries are indexed, last rebuilt 2026-11-06. Las páginas en español también aparecen en estos resultados. The clinical trial records are not in this index — they have their own finder, which searches all trial titles, sponsors and drugs directly.